Abiomed (ABMD) Halted Ahead of FDA Meeting on Blood Pumps
- Market Wrap: Market Rally Fades as DJIA Ends Q1 Negative; Charter's Smart M&A Move; Etsy Sets IPO Price Range
- Sears Holdings (SHLD), General Growth (GGP) Enter Real Estate Joint Venture
- Fed's Lacker Sees 'Strong' Case for June 'Liftoff'
- After-Hours Stock Movers 03/31: (DYAX) (CHK) (RUBI) Higher; (UTIW) (RKT) (SNX) Lower (more...)
- Etsy (ETSY) Sees IPO Price of $14 - $16/Share
Abiomed, Inc. (NASDAQ: ABMD) halted ahead of FDA advisory committee meeting over nonroller-type cardiopulmonary bypass blood pumps.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Idera Pharma (IDRA) DBCL treatment gets FDA orphan status
- RedHill Biopharma (RDHL) Announces Acquisition of ABC294640, IP Rights
- Dyax Corp (DYAX) Announces Positive Results from Phase 1b Trial of DX-2930 and Fast Track Designation
Create E-mail Alert Related CategoriesFDA, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!